Crinetics Pharmaceuticals, Inc.
CRNXNasdaq
$83.86
↓ -0.1%Jul 17 close · end-of-day
Price
1Y↑ +162.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$8.7B
Enterprise Value
$7.4B
P/E
—
P/S
483.1
P/B
6.8
EV/EBITDA
—
PEG
—
FCF Yield
-4.8%
Dividend Yield
—
Revenue (TTM)
$18.1M
Net Income (TTM)
-$496.4M
Free Cash Flow (TTM)
-$419.5M
Gross Margin
—
Operating Margin
-3020.3%
Net Margin
-2747.1%
ROE
-38.8%
ROIC
—
Debt / Equity
—
Net Cash
$1.3B
Return 1Y
+154.0%
Company profile
Crinetics Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism.
- CEO
- Scott R. Struthers
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 210
- Headquarters
- California
- Website
- crinetics.com
Management & directors
- Struthers Richard ScottPresident & CEO
- Knight Jeff E.Chief Dev. & Operating Officer
- Betz Stephen F.Chief Scientific Officer
- Schilke TobinChief Financial Officer
- Kalofonos IsabelChief Commercial Officer
- Pizzuti DanaChief Med and Dev Officer
Roles derived from SEC Form 4 filings.
Earnings
CRNX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$10.7M↑ +2873.4%
Diluted EPS-$1.23↑ +18.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $71,000.00 | $1.1M | $4.7M | $4.0M | $1.0M | $7.7M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$75.0M | -$107.7M | -$167.9M | -$222.6M | -$338.9M | -$516.8M |
| Net income | -$73.8M | -$107.6M | -$163.9M | -$214.5M | -$298.4M | -$465.3M |
| Diluted EPS | -$2.42 | -$2.80 | -$3.15 | -$3.69 | -$3.69 | -$4.95 |
| Operating cash flow | -$62.0M | -$88.6M | -$115.2M | -$168.6M | -$230.2M | -$377.9M |
| Free cash flow | -$62.2M | -$89.0M | -$116.9M | -$173.3M | -$234.0M | -$383.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -105567.6% | -9990.9% | -3544.1% | -5547.2% | -32613.5% | -6714.8% |
| Net margin | -103960.6% | -9981.4% | -3460.0% | -5345.1% | -28719.9% | -6046.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $399,000.00 | $0.00 | $0.00 | $361,000.00 | $1.0M | $143,000.00 | $6.2M | $10.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$82.8M | -$87.8M | -$94.7M | -$111.4M | -$129.1M | -$142.6M | -$133.7M | -$140.4M |
| Net income | -$74.1M | -$76.8M | -$80.6M | -$96.8M | -$115.6M | -$130.1M | -$122.8M | -$127.8M |
| Diluted EPS | -$0.94 | -$0.96 | -$0.86 | -$1.04 | -$1.23 | -$1.38 | -$1.30 | -$1.23 |
| Operating cash flow | -$47.6M | -$62.8M | -$66.9M | -$88.5M | -$85.9M | -$110.7M | -$92.9M | -$124.7M |
| Free cash flow | -$48.6M | -$63.4M | -$67.9M | -$89.7M | -$89.1M | -$111.6M | -$93.4M | -$125.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -20747.6% | — | — | -30860.1% | -12523.0% | -99710.5% | -2169.6% | -1307.8% |
| Net margin | -18560.2% | — | — | -26807.2% | -11216.0% | -90972.7% | -1993.2% | -1191.0% |
Company news
Jul 15, 2026
Jul 14, 2026
Jul 13, 2026
Jul 11, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-02 | Vivaldi Coelho Rogerio | Sale | 3,000 | $40.00 | $120,000.00 | filing |
| 2026-06-18 | Bedrosian Camille L | Award | 5,925 | $0.00 | $0.00 | filing |
| 2026-06-18 | WIERENGA WENDELL | Award | 5,925 | $0.00 | $0.00 | filing |
| 2026-06-18 | Okey Stephanie | Award | 5,925 | $0.00 | $0.00 | filing |
| 2026-06-18 | Vivaldi Coelho Rogerio | Award | 5,925 | $0.00 | $0.00 | filing |
| 2026-06-18 | Fust Matthew K | Award | 5,925 | $0.00 | $0.00 | filing |
| 2026-06-18 | Nichols Weston | Award | 5,925 | $0.00 | $0.00 | filing |
| 2026-06-18 | Deardorf Caren | Award | 5,925 | $0.00 | $0.00 | filing |
| 2026-06-17 | Okey Stephanie | Sale | 6,292 | $35.62 | $224,121.04 | filing |
| 2026-06-17 | Okey Stephanie | Sale | 608 | $36.22 | $22,021.76 | filing |
| 2026-05-29 | Struthers Richard Scott· President & CEO | Gift | 111,100 | $0.00 | $0.00 | filing |
| 2026-05-29 | Struthers Richard Scott· President & CEO | Gift | 111,100 | $0.00 | $0.00 | filing |
| 2026-05-29 | Struthers Richard Scott· President & CEO | Gift | 111,100 | $0.00 | $0.00 | filing |
| 2026-05-29 | Struthers Richard Scott· President & CEO | Gift | 111,100 | $0.00 | $0.00 | filing |
| 2026-05-29 | Struthers Richard Scott· President & CEO | Gift | 222,200 | $0.00 | $0.00 | filing |
| 2026-05-29 | Struthers Richard Scott· President & CEO | Gift | 222,200 | $0.00 | $0.00 | filing |
| 2026-05-29 | Struthers Richard Scott· President & CEO | Gift | 222,200 | $0.00 | $0.00 | filing |
| 2026-05-29 | Struthers Richard Scott· President & CEO | Gift | 80,000 | $0.00 | $0.00 | filing |
| 2026-05-29 | Struthers Richard Scott· President & CEO | Gift | 222,200 | $0.00 | $0.00 | filing |
| 2026-05-29 | Struthers Richard Scott· President & CEO | Gift | 80,000 | $0.00 | $0.00 | filing |
| 2026-05-29 | Struthers Richard Scott· President & CEO | Gift | 111,100 | $0.00 | $0.00 | filing |
| 2026-05-29 | Struthers Richard Scott· President & CEO | Gift | 111,100 | $0.00 | $0.00 | filing |
| 2026-05-29 | Struthers Richard Scott· President & CEO | Gift | 111,100 | $0.00 | $0.00 | filing |
| 2026-05-29 | Struthers Richard Scott· President & CEO | Gift | 111,100 | $0.00 | $0.00 | filing |
| 2026-04-08 | Knight Jeff E.· Chief Dev. & Operating Officer | Sale | 85,163 | $40.10 | $3.4M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.